ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO754

Evaluation of Biocompatibility and Cytotoxic Effects of New Sorbent Cartridges for Blood Hemoperfusion

Session Information

  • Bioengineering
    October 25, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Bioengineering

  • 300 Bioengineering

Authors

  • Pomare' Montin, Diego, IRRIV, Vicenza, Italy
  • Ankawi, Ghada A., UWO, LONDON, Canada
  • Lorenzin, Anna, IRRIV, Vicenza, Italy
  • Neri, Mauro, San Bortolo Hospital, Vicenza, Italy
  • Caprara, Carlotta, IRRIV, Vicenza, Italy
  • Ronco, Claudio, Ospedale "S. Bortolo" AZ. ULSS 6, Vicenza, Italy
Background

Adsorption cartridges applied in extracorporeal purification therapies, involve direct contact of blood with the sorbent material. The potential induced cytotoxicity is an important issue. The aim of this study was to investigate potential in vitro cytotoxic effects of sorbent cartridges HA130, HA230, HA330/380 (Jafron, China) on U937 monocytes.

Methods

Monocytes were exposed to the sorbent material in static and dynamic manners. In static test, cell medium samples were collected after 24 hrs of incubation in the cartridges. In dynamic test, hemoperfusion modality has been carried out and samples at 30, 60, 90 and 120 min were collected.

Results

Compared to control samples, the viability remained the same and there was no evidence of increased necrosis or apoptosis in monocytes exposed to the cartridges in the static tests (fig.1). Similarly, there was no remarkable difference in the viability, apoptosis and necrosis of U937 between each sample and the controls during the dynamic test (fig.2).

Conclusion

Our in vitro testing suggests that HA130, HA230, HA330/380 cartridges possess an optimal level of biocompatibility and their use in HP is not associated with adverse reactions or signs of cytotoxicity.